Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Protagonist/J&J Explore Autoimmune FRONTIER With Positive Psoriasis Results

Executive Summary

While full data are not yet available, JNJ-2113 would be the first oral drug against IL-23R, setting up for potential competition against oral TYK2 and IL-17-targeting drugs.

You may also be interested in...



Protagonist Hopes For ‘Paradigm Change’ With Polycythemia Drug But Needs Phase III Safety Data

The company’s late-breaker data suggests it is on the path to success in polycythemia vera, but cancer fears must be addressed with ongoing longer-term study.

Finance Watch: Lucky Few Raise Cash While Many Public Biotechs Cut Costs

Public Company Edition: ImmunoGen received the first $75m under a $175m term loan, while Protagonist raised $100m in a follow-on offering, but companies with bankruptcy filings and job cuts outpaced those accessing new capital by a wide margin in late March and early April.

Protagonist Weaves Positive Story From Mixed Phase II Data In Ulcerative Colitis

The company is pushing ahead into Phase III development with the lower dose of an oral drug for ulcerative colitis, even though a Phase II study missed the primary endpoint.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148014

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel